Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Seeking Alpha7/29/2026Neutral
AXGN
Axogen IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$2.19B
P/E Ratio
—
EPS
$-0.64
Beta
1.09
52W High
$46.95
52W Low
$12.39
50-Day MA
$42.01
200-Day MA
$33.68
Dividend Yield
—
Profit Margin
-13.20%
Forward P/E
357.14
PEG Ratio
99.04
About Axogen Inc
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Fundamentals
| Revenue (TTM) | $238.10M |
| Gross Profit (TTM) | $178.61M |
| EBITDA | $-2.13M |
| Operating Margin | -4.61% |
| Return on Equity | -18.00% |
| Return on Assets | -2.32% |
| Revenue/Share (TTM) | $5.00 |
| Book Value | $4.61 |
| Price-to-Book | 8.93 |
| Price-to-Sales (TTM) | 9.19 |
| EV/Revenue | 8.85 |
| EV/EBITDA | 4083.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 26.60% |
| Shares Outstanding | $53.18M |
| Float | $52.02M |
| % Insiders | 2.19% |
| % Institutions | 96.45% |
Historical Volatility
HV 10-Day
29.64%
HV 20-Day
48.37%
HV 30-Day
45.39%
HV 60-Day
40.98%
HV Rank
28.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($50.78 target)
2
Strong Buy7
BuyLatest News
AxoGen Q2 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
MarketBeat7/29/2026Neutral
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Zacks Investment Research7/29/2026Positive
Axogen, Inc. Reports Second Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire7/29/2026Neutral
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
GlobeNewsWire7/15/2026Neutral
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
MarketBeat5/14/2026Positive
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire4/30/2026Neutral
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Zacks Investment Research4/28/2026Negative
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
GlobeNewsWire4/28/2026Neutral
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research4/21/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026